93 related articles for article (PubMed ID: 15280844)
21. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris.
Magliocco MA; Pandya K; Dombrovskiy V; Christiansen L; Wong Y; Gottlieb AB
J Am Acad Dermatol; 2006 Jan; 54(1):115-8. PubMed ID: 16384765
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.
Read WL; Baggstrom MQ; Fracasso PM; Govindan R
Chemotherapy; 2008; 54(3):236-41. PubMed ID: 18560232
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
28. Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Musolino A; Panebianco M; Zendri E; Santini M; Di Nuzzo S; Ardizzoni A
Br J Haematol; 2009 Apr; 145(1):84-6. PubMed ID: 19208096
[TBL] [Abstract][Full Text] [Related]
29. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis.
Beutner K; Chakrabarty A; Lemke S; Yu K
J Drugs Dermatol; 2006 Apr; 5(4):357-60. PubMed ID: 16673804
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A
Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580
[TBL] [Abstract][Full Text] [Related]
31. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
32. A multiparameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion.
Franssen ME; Smit JV; Van Erp PE; Van De Kerkhof PC
Br J Dermatol; 2003 Sep; 149(3):506-12. PubMed ID: 14510982
[TBL] [Abstract][Full Text] [Related]
33. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
34. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
35. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Scarisbrick JJ; Morris S; Azurdia R; Illidge T; Parry E; Graham-Brown R; Cowan R; Gallop-Evans E; Wachsmuth R; Eagle M; Wierzbicki AS; Soran H; Whittaker S; Wain EM
Br J Dermatol; 2013 Jan; 168(1):192-200. PubMed ID: 22963233
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.
Liu YY; Stokkel MP; Morreau HA; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2008 Apr; 68(4):605-9. PubMed ID: 17986279
[TBL] [Abstract][Full Text] [Related]
37. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
38. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis.
Zhu X; Wang B; Zhao G; Gu J; Chen Z; Briantais P; Andres P
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):466-72. PubMed ID: 17373972
[TBL] [Abstract][Full Text] [Related]
39. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
40. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.
Lebwohl M; Menter A; Weiss J; Clark SD; Flores J; Powers J; Balin AK; Kempers S; Glinert RJ; Fleming T; Liu Y; Graeber M; Pariser DM
J Drugs Dermatol; 2007 Apr; 6(4):428-35. PubMed ID: 17668541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
